Arcadia Biosciences stock trades at $0.52 as market cap slips to $1.28 million
Published on 08/29/2026 at 15:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Arcadia Biosciences (US03020Q1058) stock is quoted at $0.52 as of August 29, 2026, valuing the agricultural biotechnology company at $1.28 million based on recent market data. The low price underscores how investor confidence has been tested as the company works to translate its seed and ingredient technologies into sustainable revenue growth.
RKDA share price and trading context
Per recent quote data, Arcadia Biosciences stock changed hands at a high of $0.55 and a low of $0.50 during the trading session of August 29, 2026. At the current price of $0.52, the shares trade 5.3% above the session low and 4.6% below the session high, highlighting intraday volatility in a thinly capitalized name. With a market capitalization of $1.28 million at this price, the company sits firmly in micro-cap territory, where modest shifts in trading interest can have a significant percentage impact on the share price.
The same quote snapshot indicates a price-to-earnings ratio of -0.12 for Arcadia Biosciences as of August 29, 2026, reflecting that the company is loss-making on a trailing earnings basis. A negative P/E ratio typically signals that net income over the latest reported period is below zero, and the small absolute value of the ratio suggests that the market is assigning only a limited valuation premium to the company’s current earnings profile. For investors, this combination of low market value and negative P/E underlines that the equity story depends more on future execution than on current profits.
Interpreting valuation and risk at current levels
At a share price of $0.52 and a market cap of $1.28 million as of August 29, 2026, Arcadia Biosciences’ valuation leaves little room for missteps, but also creates leverage to any material operational improvement. When a company trades at this low an absolute equity value, outcomes often skew to extremes: either a successful restructuring or commercialization push can drive substantial percentage gains, or continued losses and capital needs can dilute existing shareholders further. The negative P/E ratio of -0.12 reinforces that the current valuation is not supported by positive earnings, which raises the importance of cash management and access to financing.
The intraday range between $0.50 and $0.55 on August 29, 2026, combined with the 5.3% spread between the low and the current price, hints that even modest buying or selling can move the stock meaningfully within a single session. For short-term traders, such volatility offers opportunities but also magnifies risk, while longer-term investors often focus instead on whether the company’s technology pipeline and commercial agreements can justify a higher sustainable valuation over time.
Core products and business focus
Arcadia Biosciences focuses on developing and commercializing agricultural and food ingredient traits designed to improve crop performance and deliver consumer health benefits. The company’s portfolio spans areas such as enhanced nutritional content in grains and improved agronomic characteristics in key crops. This model aims to generate revenue from trait licensing, seed sales and branded consumer ingredients, positioning the company at the intersection of biotechnology and food production.
Stock snapshot and investor takeaway
Arcadia Biosciences trades on the Nasdaq in US dollars, and its stock price of $0.52 as of August 29, 2026, reflects both the challenges and optionality inherent in a small-cap biotech with an applied agriculture focus. The market capitalization of $1.28 million and the negative P/E ratio of -0.12 signal that investors currently assign a very modest value to its pipeline and existing operations. For investors following RKDA, the key questions now center on when the company can deliver consistent revenue growth and move its earnings profile closer to break-even, which would be needed to support a structurally higher share price.
Fact box
Company: Arcadia Biosciences Inc.
ISIN: US03020Q1058
Ticker: RKDA
Exchange: Nasdaq
Price (as of August 29, 2026): $0.52 USD
Market cap: $1.28 million (as of August 29, 2026)
Sector / Industry: Health Care / Biotechnology
